Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

TECcare™ Ultra passes EPA approved test for killing Clostridium difficile spores.

Talley Environmental Care
Posted on: 11 Jun 09

Talley Environmental Care Ltd are delighted to announce that TECcare Ultra has become the first and only product to have passed the new stringent Environmental Protection Agency (EPA) approved testing protocol for killing Clostridium Difficile (C. difficile) spores under Good Laboratory Practice (GLP) conditions.

The EPA has stated that C. difficile is a microorganism that has been implicated as a cause of potentially dangerous diarrheal illness. In 2008 EPA reversed its decision to allow disinfectant product label claims for the vegetative form of the organism, C. difficile. Their decision was made in light of current research demonstrating that the spore form is persistent on environmental surfaces and is implicated in the spread of diarrhea associated with C. difficile. In addition, products effective against only the vegetative form could spread the spores and increase the possibility of infection. Given this information, the Agency believes products with claims of efficacy against only the vegetative form of the organism pose unreasonable risks of harm to health and the environment. Registrants were contacted and required to eliminate label claims for this organism until sporicidal data against C. difficile is generated.

The Agency has posted interim guidance for efficacy testing to obtain the C. difficile sporicidal claim for hard non-porous surfaces. A copy of the guidance is available on the EPA website.

According to a survey conducted by the Association for Professionals in Infection Control and Epidemiology (APIC). "The National Point Prevalence of C. difficile in U.S. Healthcare Facility Inpatients, 2008" indicated that 13 out of every 1,000 inpatients were either infected or colonized with C. difficile . This rate is 6.5 to 20 times greater than previous incidence estimates and based on this rate, the costs associated are estimated to be $17.6 to $51.5 million.

These latest EPA approved testing protocols also confirms the findings of previous independent testing carried out in Europe by the Leiden University Reference Centre for C. difficile Research, that showed that the TECcare™ Ultra is highly effective at killing C. difficile in spore form.

Commenting on the testing Kevin Mearns, Director of Business Development said;
“…Passing these latest approved tests once again highlights the excellent efficacy of TECcare Ultra, and combined with its exceptional safety credentials the product has been proven to kill this potentially life threatening pathogen..TECcare Ultra offers a true sporicial product, one that does not contain damaging chemicals and skin irritants such as bleach, alcohols, phenols, chlorine and aldehydes and is well suited for repeated use on surfaces. It is safe and effective as well as being fully biodegradable and environmentally friendly..”

The TECcare™ technology platform can be used in a variety of areas including Healthcare, Pharmaceuticals, Advanced Wound care, Dentistry, Food and Beverage, Hospitality and Leisure, Water Treatment, Industrial Applications, Schools and Nurseries and for General Domestic Hygiene.

For more information:

Editor's Details

K Mearns
Talley Environmental Care

Last updated on: 27/08/2010

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.